Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.
Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.
Dr de Cogan said: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye.
“From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
“Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD.
“They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen, said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and clinical trials.
“We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good Newson June 25, 2020 at 9:33 am
Iveric Bio's stock surged 78% last week to reach $6.65 on positive data from an 18-month trial of its C5 inhibitor Zimura in patients with Geographic Atrophy. T ...
- U.S. Government Alleges Regeneron Used Kickbacks to Boost Eylea Saleson June 25, 2020 at 9:28 am
Regeneron Pharmaceuticals said the company will vigorously defend federal charges of being involved in a kickback scheme to bolster sales of the blockbuster macular degeneration drug Eylea.
- Federal government accuses Regeneron of kickback scheme for top-selling drugon June 24, 2020 at 4:08 pm
In a lawsuit, the U.S. attorney's office in Boston alleged Regeneron used a charity as a "conduit" to cover patient co-pays for its eye drug Eylea.
- Regeneron Paid Kickbacks To Boost Eye Drug, Feds Sayon June 24, 2020 at 3:53 pm
Federal prosecutors in Massachusetts accused New York pharmaceutical company Regeneron Pharmaceuticals on Wednesday of paying tens of millions of dollars in illegal kickbacks through a foundation to ...
- AsclepiX Launches to Study Eye and Cancer Diseaseson June 24, 2020 at 8:46 am
AsclepiX focuses on leveraging computational biology to find peptide regulators of vascular homeostasis for retinal and other diseases. The funds will go toward Phase I/IIa clinical trials of AXT107, ...
- Lineage Cell Therapeutics to Present OpRegen® Data at International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meetingon June 24, 2020 at 5:01 am
The International Society for Stem Cell Research has transformed its annual scientific meeting into a virtual experience, bringing the global stem cell community together to share knowledge, ...
- AsclepiX Therapeutics Announces $35 Million Series A Financingon June 24, 2020 at 3:55 am
AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important ...
- Macular Degeneration Treatment Market to Proliferate at a Healthy CAGR of 7.3% by 2027on June 23, 2020 at 2:53 am
The global Macular Degeneration Treatment Market size is expected to reach USD 11.4 billion by 2027, at a significant growth rate of 6.6 % during the forecasted period 2020 to 2027. The market report ...
- Plastic membrane to treat age-related macular degenerationon June 19, 2020 at 7:51 am
A porous polymeric scaffold might be the answer to a sight problem that afflicts millions of older people every year, age-related macular degeneration. Researchers writing in the International Journal ...
via Bing News